Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment
Johannes Thrul, Albert Garcia‐romeu
Drugs Education Prevention and Policy April 30, 2021 DOI: 10.1080/09687637.2021.1897331 via OpenAlex
Summary
AI-generated from the abstractResearch into the therapeutic potential of highly restricted Schedule I hallucinogens, such as the classic psychedelic psilocybin and the entactogen MDMA, is expanding. These substances, long prohibited under federal law, are now being studied for possible benefits in mental health treatment, though their legal status limits investigation.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Hallucinogen Mental health Psychiatry Clinical psychology |
| Citations | 78 |
| Key finding | Research on therapeutic applications of Schedule I hallucinogens like psilocybin and MDMA is growing despite legal restrictions. |
Abstract
Growing research on potential therapeutic applications of highly restricted Schedule I hallucinogens, including the ‘classic psychedelic’ psilocybin, and the entactogen 3,4-Methylenedioxymethamphet...